TMCI250117C2500
- 0.00
- 0.000.00%
Treace Medical Concepts Newsroom
Treace to Present at 43rd Annual J.P. Morgan Healthcare Conference
Sector Update: Health Care Stocks Mixed Late Afternoon
This Vertex Analyst Begins Coverage On A Bullish Note; Here Are Top Initiations For Tuesday
Lake Street Initiates Treace Medical Concepts(TMCI.US) With Buy Rating, Announces Target Price $14.5
Treace Expands Reach Into High-Volume Osteotomy Market With Second MIS Osteotomy Platform, Percuplasty Percutaneous 3D Bunion Correction Procedure
With 54% Institutional Ownership, Treace Medical Concepts, Inc. (NASDAQ:TMCI) Is a Favorite Amongst the Big Guns
Is Treace Medical Concepts (NASDAQ:TMCI) Weighed On By Its Debt Load?
Truist Financial Maintains Treace Medical Concepts(TMCI.US) With Hold Rating, Raises Target Price to $8.4
Express News | Treace Medical Concepts Inc : Truist Securities Raises Target Price to $8.4 From $7
Express News | JP Morgan Assumes Treace Medical Concepts at Neutral, Announces Price Target of $8
Treace Announces First Surgical Cases Utilizing the SpeedPlate MicroQuad Implant
Treace Announces First Cases Utilizing RedPoint Intelliguide Patient Specific Instrumentation With the Adductoplasty System for Correction of Midfoot Deformities
Press Release: Treace Appoints Guy Guglielmino as Chief Commercial Officer
Express News | Treace Appoints Guy Guglielmino as Chief Commercial Officer
Treace Announces Participation at Stifel 2024 Healthcare Conference
US$7.50 - That's What Analysts Think Treace Medical Concepts, Inc. (NASDAQ:TMCI) Is Worth After These Results
Treace Medical Concepts Third Quarter 2024 Earnings: Beats Expectations
Nasdaq Surges Over 500 Points; Johnson Controls Earnings Top Views
Treace Medical Concepts Analyst Ratings
Gold Down Over 2%; CVS Health Shares Jump After Q3 Results